Prostate最新文献

筛选
英文 中文
Prognostic Nutritional Index as a Biomarker in Metastatic Hormone-Sensitive Prostate Cancer: Impact on Survival and Treatment Optimization.
IF 2.6 3区 医学
Prostate Pub Date : 2025-02-19 DOI: 10.1002/pros.24876
Muhammet Bekir Hacioglu, Ahmet Kucukarda, Ivo Gokmen, Ali Fuat Gurbuz, Murat Araz, Fatma Akdag Kahvecioglu, Ilhan Hacibekiroglu, Orhun Akdoğan, Ozan Yazıcı, Fatma Aysun Akkus, Abdussamet Çelebi, Osman Kostek, Bulent Erdogan
{"title":"Prognostic Nutritional Index as a Biomarker in Metastatic Hormone-Sensitive Prostate Cancer: Impact on Survival and Treatment Optimization.","authors":"Muhammet Bekir Hacioglu, Ahmet Kucukarda, Ivo Gokmen, Ali Fuat Gurbuz, Murat Araz, Fatma Akdag Kahvecioglu, Ilhan Hacibekiroglu, Orhun Akdoğan, Ozan Yazıcı, Fatma Aysun Akkus, Abdussamet Çelebi, Osman Kostek, Bulent Erdogan","doi":"10.1002/pros.24876","DOIUrl":"https://doi.org/10.1002/pros.24876","url":null,"abstract":"<p><strong>Objective: </strong>The Prognostic Nutritional Index (PNI), reflects the nutritional and immunological status of the patient and has been associated with outcomes in various cancers. In this study, the prognostic significance of PNI in metastatic hormone-sensitive prostate cancer (mHSPC) and its potential role in guiding treatment decisions between abiraterone acetate and enzalutamide is investigated.</p><p><strong>Methods: </strong>Retrospective analysis was performed on 167 mHSPC patients treated between 2019 and 2024. PNI was calculated using the formula: 10 × serum albumin (g/dL) + 0.005 × total lymphocyte count (/mm³). Patients were stratified into high and low PNI groups according to a cutoff value of 49.98, determined via receiver operating characteristic (ROC) analysis. Survival outcomes, including overall survival (OS), radiographic progression-free survival (rPFS), and PSA progression-free survival (PSA-PFS), were assessed. Treatment responses to abiraterone acetate and enzalutamide were compared within PNI strata.</p><p><strong>Results: </strong>Patients with PNI > 49.98 had significantly longer median OS than those with PNI ≤ 49.98 (36.6 months vs. 30.0 months, p < 0.01). Multivariate analysis identified high PNI, ECOG performance status 0-1, and absence of visceral metastasis as independent predictors of improved OS. Among patients with low PNI, those treated with enzalutamide had superior OS compared to those receiving abiraterone acetate (p = 0.004), while no significant OS difference was noted between treatments in the high PNI group (p = 0.55).</p><p><strong>Conclusion: </strong>PNI serves as a significant prognostic biomarker in mHSPC, correlating with overall survival and potentially influencing treatment efficacy between abiraterone acetate and enzalutamide. Integrating PNI into clinical practice may aid in tailoring individualized treatment options.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143460587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In Vivo Efficacy of a Macrocyclic Peptoid-Peptide Hybrid That Selectively Modulates the Beta-Catenin/TCF Interaction to Inhibit Prostate Cancer.
IF 2.6 3区 医学
Prostate Pub Date : 2025-02-16 DOI: 10.1002/pros.24868
Justine Habault, Jennifer L Franco, Susan Ha, Jeffry A Schneider, Maud Voisin, David R Wise, Kwok-Kin Wong, Michael J Garabedian, Kent Kirshenbaum, Susan K Logan
{"title":"In Vivo Efficacy of a Macrocyclic Peptoid-Peptide Hybrid That Selectively Modulates the Beta-Catenin/TCF Interaction to Inhibit Prostate Cancer.","authors":"Justine Habault, Jennifer L Franco, Susan Ha, Jeffry A Schneider, Maud Voisin, David R Wise, Kwok-Kin Wong, Michael J Garabedian, Kent Kirshenbaum, Susan K Logan","doi":"10.1002/pros.24868","DOIUrl":"10.1002/pros.24868","url":null,"abstract":"<p><strong>Background: </strong>Prostate cancer is the most common form of male cancer and can initially be treated as a localized disease. Although the 5-year survival rate at diagnosis approaches 100 percent, a subset of patients will subsequently develop resistance to treatment. This may ultimately lead to metastatic castration resistant prostate cancer (mCRPC), for which the prognosis is much less favorable. The importance of the Wnt/β-catenin pathway in treatment-resistant prostate cancer has inspired efforts to exploit the interaction of β-catenin with its transcription binding partners as a therapeutic strategy for prostate cancer.</p><p><strong>Methods: </strong>Peptoid-peptide macrocycles are attractive design scaffolds for disrupting protein-protein interactions. In this study, we evaluate a library of these macrocycles and demonstrate their selectivity for the β-catenin/TCF (T Cell Factor) interaction.</p><p><strong>Results: </strong>Importantly, we show that the macrocycles do not significantly alter the binding of β-catenin to cell surface protein, E-cadherin. Our lead sequence, Macrocycle 13, (MC13) was also tolerant of modifications aimed to improve aqueous solubility while retaining activity. Herein, we demonstrate in vivo proof of principle for using peptidomimetic macrocycles to target the β-catenin/TCF interaction. Treated prostate cancer mouse xenografts show markedly diminished tumor growth and decreased levels of myc protein. MC13 also inhibits growth in an organoid model with genetic alterations frequently found in prostate cancer. Transcriptome analysis of prostate cancer cells treated with MC13 reveals downregulation of key pathways, including Wnt/β-catenin and c-myc. Furthermore, chromatin immunoprecipitation (ChIP) analysis shows reduced β-catenin at its target genes, axin2 and c-myc.</p><p><strong>Conclusion: </strong>Our findings underscore the therapeutic potential of peptoid-peptide macrocycle inhibition of β-catenin in prostate cancer.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"e24868"},"PeriodicalIF":2.6,"publicationDate":"2025-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143434386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Progression-Free Survival Prediction Performance of ChatGPT: Analysis With Real Life Data in Early and Locally Advanced Prostate Cancer.
IF 2.6 3区 医学
Prostate Pub Date : 2025-02-13 DOI: 10.1002/pros.24871
Engin Eren Kavak, İsmail Dilli
{"title":"Progression-Free Survival Prediction Performance of ChatGPT: Analysis With Real Life Data in Early and Locally Advanced Prostate Cancer.","authors":"Engin Eren Kavak, İsmail Dilli","doi":"10.1002/pros.24871","DOIUrl":"https://doi.org/10.1002/pros.24871","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the progression-free survival (PFS) time in patients with early-stage and locally advanced prostate cancer and to compare the estimates provided by ChatGPT with actual survival data.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on patients diagnosed with early-stage/locally advanced prostate cancer. Each patient's estimated PFS times were calculated using an artificial intelligence chatbot. These estimates were generated by considering several factors, including the patient's clinical characteristics, tumor stage, treatment modalities, and biochemical parameters. A statistical comparison was conducted between the predicted PFS and actual PFS times.</p><p><strong>Results: </strong>The AI chatbot tended to overestimate the overall PFS times. A statistically significant discrepancy was observed between the predicted and actual survival times (p < 0.05). A discrepancy of 9.19 months was observed between the PFS predictions made by ChatGPT and the actual PFS. The bias value was 48.57, yet this discrepancy had a negligible impact on clinical practice (Cohen's d = 0.189).</p><p><strong>Discussion: </strong>Artificial intelligence-based models have the potential to play an important role in the prediction of progression in cancers such as prostate cancer, where 5-10-year survival rates can reach 100%. However, this study's findings indicate that the AI model's predictions are not aligned with the actual clinical data. The reliability of the integration of artificial intelligence into clinical decision support systems can be enhanced through the undertaking of comprehensive future studies.</p><p><strong>Conclusion: </strong>The use of artificial intelligence in predictive modeling may prove an effective approach for forecasting the PFS of prostate cancer. It has the potential to supplant the nomograms that are currently in use. Nevertheless, further studies are required to substantiate the accuracy and reliability of these systems.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"e24871"},"PeriodicalIF":2.6,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143416427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Current Status of Prostate Biopsy in Africa: Are We Ready for a Targeted Biopsy?
IF 2.6 3区 医学
Prostate Pub Date : 2025-02-06 DOI: 10.1002/pros.24867
Ziba Ouima Justin Dieudonne, Kaleab Habtemichae Gebreselassie, Taofiq Olayinka Mohammed, Abdullahi Khalid, Saleh Abdelkerim Nedjim, Anteneh Tadesse Kifle, Marcella D C Biyouma, Hassan Dogo, Christian Agbo, Muhawenimana Emmanuel, Mahamat Ali Mahamat, Ndoye Alain Khassim, Lazarus John, Yameogo Clotaire Alexis Marie Kiemdiba Donega, Mohamed Lezrek, Kirakoya Brahima, Ouattara Adama, Kabore Fasnewende Aristide
{"title":"Current Status of Prostate Biopsy in Africa: Are We Ready for a Targeted Biopsy?","authors":"Ziba Ouima Justin Dieudonne, Kaleab Habtemichae Gebreselassie, Taofiq Olayinka Mohammed, Abdullahi Khalid, Saleh Abdelkerim Nedjim, Anteneh Tadesse Kifle, Marcella D C Biyouma, Hassan Dogo, Christian Agbo, Muhawenimana Emmanuel, Mahamat Ali Mahamat, Ndoye Alain Khassim, Lazarus John, Yameogo Clotaire Alexis Marie Kiemdiba Donega, Mohamed Lezrek, Kirakoya Brahima, Ouattara Adama, Kabore Fasnewende Aristide","doi":"10.1002/pros.24867","DOIUrl":"https://doi.org/10.1002/pros.24867","url":null,"abstract":"<p><strong>Background: </strong>Prostate cancer remains a significant public health issue globally, with considerable disparities in diagnostic and management practices, especially in Africa. Traditional diagnostic methods such as transrectal ultrasound-guided biopsies have limitations in accuracy and are associated with potential complications. Emerging targeted biopsy techniques promise improved cancer detection rates and reduced morbidity but face adoption challenges across the African continent due to variable access to advanced imaging technologies and professional expertise.</p><p><strong>Objective: </strong>This study aims to evaluate the current practices of prostate biopsy techniques in Africa, focusing particularly on the readiness for and integration of targeted biopsy methods. It assesses the accessibility, quality, volume of procedures, and availability of advanced diagnostic tools across different regions.</p><p><strong>Results: </strong>The survey included 58 centers across five African regions, representing a 70% response rate from an initial 83 invitations sent. Finger-guided biopsy was the most common method, used by 41 centers, while only one center reported using MRI fusion biopsy. Thirty-five centers routinely administered a rectal enema, and nearly all (n = 50) centers employed antibiotic prophylaxis, predominantly fluoroquinolones. For anesthesia, 12 centers used injectable lidocaine, and 38 centers used intrarectal lidocaine gel. The number of biopsy cores taken varied, with most centers taking 12, while others used fewer.</p><p><strong>Conclusion: </strong>The findings indicate a critical need for concerted efforts to bridge the gap in prostate cancer diagnostics and treatment in Africa. Enhancing the quality of prostate cancer care on the continent requires investments in training, infrastructure, and standardization of practices. Collaborative efforts towards adopting advanced diagnostic tools and methods are essential for aligning African practices with global standards, ultimately improving outcomes for prostate cancer patients.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"e24867"},"PeriodicalIF":2.6,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143366831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Does size matter? A single institution's comparison of Aquablation in prostates greater than or less than 150 mL. 大小是否重要?一家医疗机构对大于或小于 150 毫升前列腺的水消融术进行的比较。
IF 2.6 3区 医学
Prostate Pub Date : 2025-02-01 Epub Date: 2024-10-15 DOI: 10.1002/pros.24810
Renee Ringler, David Gangwish, Paul Horning, Joshua Kuperus, Greg Palmateer, Bernadette M M Zwaans, Jason Hafron, Kenneth M Peters
{"title":"Does size matter? A single institution's comparison of Aquablation in prostates greater than or less than 150 mL.","authors":"Renee Ringler, David Gangwish, Paul Horning, Joshua Kuperus, Greg Palmateer, Bernadette M M Zwaans, Jason Hafron, Kenneth M Peters","doi":"10.1002/pros.24810","DOIUrl":"10.1002/pros.24810","url":null,"abstract":"<p><strong>Background: </strong>Surgical management options for lower urinary tract symptoms due to benign prostatic hypertension have remained limited in prostates of large volume. The advent of the Aquablation has created a potential minimally invasive option for treatment in prostates of all volumes. Thus, this study aims to evaluate outcomes and complications of Aquablation in clinical practice based on prostate volume.</p><p><strong>Methods: </strong>Collected variables included adverse events with Clavien-Dindo classifications, transfusion rates, surgical retreatment rates, continued medication use postoperatively, and International Prostate Symptom Score (IPSS) with Quality-of-Life indicator. Aquablations were stratified by preoperative prostate volume.</p><p><strong>Results: </strong>One hundred seventy-four men were included in the study. The average postop decrease in IPSS was 10.28, with a 2.02 point decrease in Quality-of-Life at 1 year. Postop increase in peak urinary flow rate was 7.65 mL/s for an average of 16.44 mL/s. Hemoglobin drop average was 1.78 g/dL, but only 2.3% of patients required a transfusion. 12.9% of patients required surgical retreatment. Six months after Aquablation, 22.9% and 12.9% of patients continued taking Alpha-blockers and Androgen receptor inhibitors, respectively. Adverse events occurred in 33 patients (19.0%). Eighteen patients were excluded from secondary analysis due to unrecorded prostate volume, leaving 123 with volumes <150 mL and 33 with volumes ≥150 mL. Groups were comparable with respect to length of stay, adverse events, blood transfusion, IPSS with Quality-of-Life indicator preoperative and postoperative, postop peak urinary flow, and postop alpha-blocker use. Larger prostates had a higher rate of adverse events, retreatment, postop hemoglobin drop, and postop use of finasteride.</p><p><strong>Conclusions: </strong>Aquablation is a viable treatment option for benign prostatic hyperplasia. Efficacy, safety, subjective outcomes, and adverse event rates were not impacted by prostate volume. However, size does matter as prostates ≥150 mL had higher surgical retreatment rates and postop finasteride use.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"140-147"},"PeriodicalIF":2.6,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142481061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Investigation of pelvic floor influence on prostate displacement in image-guided radiotherapy. 图像引导放射治疗中盆底对前列腺移位影响的研究。
IF 2.6 3区 医学
Prostate Pub Date : 2025-02-01 Epub Date: 2024-10-08 DOI: 10.1002/pros.24808
Hongbo Chai, Yuya Miyasaka, Yasuhito Hagiwara, Hikaru Souda, Miyu Ishizawa, Hiraku Sato, Takeo Iwai
{"title":"Investigation of pelvic floor influence on prostate displacement in image-guided radiotherapy.","authors":"Hongbo Chai, Yuya Miyasaka, Yasuhito Hagiwara, Hikaru Souda, Miyu Ishizawa, Hiraku Sato, Takeo Iwai","doi":"10.1002/pros.24808","DOIUrl":"10.1002/pros.24808","url":null,"abstract":"<p><strong>Purpose: </strong>The uncertainty of target location during prostate cancer radiotherapy plays an important role in accurate dose delivery and radiation toxicity in adjacent organs. This study analyzed displacement correlations between the prostate and pelvic floor.</p><p><strong>Methods and materials: </strong>We retrospectively analyzed registration results from 467 daily cone-beam computed tomography (CT) in 12 patients with prostate cancer who received radiation therapy. We analyzed prostate displacement and the pelvic floor relative to the pelvic bone's anatomy in the translational and rotational directions and identified statistical correlations.</p><p><strong>Results: </strong>The systematic (Σ) and random (σ) displacements of the prostate in the three translational directions, anterior-posterior (AP), superior-inferior (SI), and right-left (RL), were 1.49 ± 1.45, 2.10 ± 1.40, and 0.24 ± 0.53 mm, respectively, and in the rotational directions of the pitch, roll, and yaw were 2.10 ± 2.02°, 0.42 ± 0.74°, and 0.42 ± 0.64°, respectively. The pelvic floor displacements were 2.37 ± 1.96, 2.71 ± 2.28, and 0.47 ± 0.84 mm in the AP, SI, and RL directions, respectively, and 0.93 ± 1.49°, 0.98 ± 1.28 °, and 0.87 ± 0.94° in the pitch, roll, and yaw directions, respectively. Additionally, there were statistically significant correlations between the displacement of the prostate and pelvic floor in the AP and SI directions, with correlation coefficients (r) of 0.74 (p < 0.001) and 0.69 (p < 0.001), respectively.</p><p><strong>Conclusions: </strong>The movement of the pelvic floor may be an important factor that causes prostate displacement, affecting the accuracy of radiotherapy. Therefore, it is necessary to take appropriate measures to ensure that the pelvic floor muscle tension is as consistent as possible in the treatment' CT scan and daily treatment.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"123-129"},"PeriodicalIF":2.6,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11648068/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142395278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Life Expectancy in High-Grade Incidental Prostate Cancer Patients Versus Population-Based Controls According to Treatment Type. 根据治疗类型划分的高级别偶发前列腺癌患者与人群对照组的预期寿命。
IF 2.6 3区 医学
Prostate Pub Date : 2025-02-01 Epub Date: 2024-10-24 DOI: 10.1002/pros.24816
Francesco Di Bello, Letizia Maria Ippolita Jannello, Andrea Baudo, Mario de Angelis, Carolin Siech, Zhe Tian, Jordan A Goyal, Massimiliano Creta, Gianluigi Califano, Giuseppe Celentano, Pietro Acquati, Fred Saad, Shahrokh F Shariat, Luca Carmignani, Ottavio de Cobelli, Alberto Briganti, Felix K H Chun, Nicola Longo, Pierre I Karakiewicz
{"title":"Life Expectancy in High-Grade Incidental Prostate Cancer Patients Versus Population-Based Controls According to Treatment Type.","authors":"Francesco Di Bello, Letizia Maria Ippolita Jannello, Andrea Baudo, Mario de Angelis, Carolin Siech, Zhe Tian, Jordan A Goyal, Massimiliano Creta, Gianluigi Califano, Giuseppe Celentano, Pietro Acquati, Fred Saad, Shahrokh F Shariat, Luca Carmignani, Ottavio de Cobelli, Alberto Briganti, Felix K H Chun, Nicola Longo, Pierre I Karakiewicz","doi":"10.1002/pros.24816","DOIUrl":"10.1002/pros.24816","url":null,"abstract":"<p><strong>Objective: </strong>To quantify the differences in 5-year overall survival (OS) between high-grade (Gleason sum 8-10) incidental prostate cancer (IPCa) patients and age-matched male population-based controls, according to treatment type: no active versus active treatment.</p><p><strong>Materials and methods: </strong>We relied on the Surveillance, Epidemiology, and End Results (SEER) database (2004-2015) to identify not actively treated and actively treated high-grade IPCa patients. For each case, we simulated an age-matched male control (Monte Carlo simulation), relying on Social Security Administration Life Tables (2004-2020) with 5 years of follow-up. Additionally, we relied on Kaplan-Meier plots to display OS for each treatment type. Multivariable Cox regression models were fitted to predict overall mortality (OM).</p><p><strong>Results: </strong>Of 564 high-grade IPCa patients, 345 (61%) were not actively treated versus 219 (39%) were actively treated, either with radical prostatectomy or radiotherapy. Median OS was 3 years for not actively treated high-grade IPCa patients, with OS difference at 5 years follow-up of 27% relative to their age-matched male population-based controls (37% vs. 64%). Median OS was 8 years for actively treated high-grade IPCa patients, with OS difference at 5 years follow-up of 6% relative to their age-matched male population-based controls (68% vs. 74%). In the multivariable Cox regression model, active treatment independently predicted lower OM (hazard ratio = 0.6; 95% confidence interval = 0.4-0.8; p < 0.001).</p><p><strong>Conclusion: </strong>Relative to Life Tables' derived age-matched male controls, not actively treated high-grade IPCa patients exhibit drastically worse OS than their actively treated counterparts. These observations may encourage clinicians to consider active treatment in newly diagnosed high-grade IPCa patients.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"191-197"},"PeriodicalIF":2.6,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142513096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CHARGE: The "Big Questions" in Prostate Cancer for 2024. CHARGE: 2024年前列腺癌的“大问题”。
IF 2.6 3区 医学
Prostate Pub Date : 2025-02-01 Epub Date: 2024-12-01 DOI: 10.1002/pros.24829
Andrea K Miyahira, Howard R Soule, Kenneth J Pienta
{"title":"CHARGE: The \"Big Questions\" in Prostate Cancer for 2024.","authors":"Andrea K Miyahira, Howard R Soule, Kenneth J Pienta","doi":"10.1002/pros.24829","DOIUrl":"10.1002/pros.24829","url":null,"abstract":"","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"227-231"},"PeriodicalIF":2.6,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142774726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and Predictive Factors Analysis of Androgen Deprivation Plus Novel Hormone Therapy as Neoadjuvant Treatment for High-Risk Prostate Cancer. 雄激素剥夺加新型激素疗法作为高危前列腺癌新辅助治疗的疗效和预测因素分析
IF 2.6 3区 医学
Prostate Pub Date : 2025-02-01 Epub Date: 2024-11-03 DOI: 10.1002/pros.24817
Hanyang Tao, Fan Wu, Rui Li, Xinxing Du, Yinjie Zhu, Liang Dong, Jiahua Pan, Baijun Dong, Wei Xue
{"title":"Efficacy and Predictive Factors Analysis of Androgen Deprivation Plus Novel Hormone Therapy as Neoadjuvant Treatment for High-Risk Prostate Cancer.","authors":"Hanyang Tao, Fan Wu, Rui Li, Xinxing Du, Yinjie Zhu, Liang Dong, Jiahua Pan, Baijun Dong, Wei Xue","doi":"10.1002/pros.24817","DOIUrl":"10.1002/pros.24817","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;This investigation explored the clinical features, pathological outcomes, and biochemical recurrence (BCR) duration among high-risk prostate cancer (HRPC) patients who have undergone neoadjuvant therapy (NAT) in combination with radical prostatectomy (RP) and pelvic lymph node dissection (PLND). Additionally, we identified prognostic indicators that discern pathological complete response (pCR) or minimal residual disease (MRD) and BCR.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;In total, we examined 76 HRPC patients, who received NAT with either androgen deprivation therapy (ADT) plus apalutamide or ADT plus abiraterone, with subsequent RP and PLND. We conducted a genetic evaluation of patients receiving neoadjuvant apalutamide. Additionally, patient pathological outcomes, circulating prostate-specific antigen (PSA) response rates, and BCR duration were analyzed. Lastly, we employed uni- and multivariate analyses to screen for prognostic factors that govern pCR or MRD and BCR duration.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Patient median age and median PSA at presentation were 69 years (IQR: 66-73), and 47.6 ng/mL (IQR: 24.1-105.75), respectively. We observed marked changes in pCR or MRD rates between the two cohorts. In particular, the ADT plus apalutamide cohort (51.5%) exhibited enhanced rates relative to the ADT plus abiraterone cohort (25.6%) (p = 0.03). The median BCR duration was substantially prolonged among neoadjuvant apalutamide cohort relative to the neoadjuvant abiraterone cohort (261 days vs. 76 days, p = 0.04). Using multivariate analysis, we revealed that the postintervention pre-RP PSA content (≤ 0.1 ng/mL vs. &gt; 0.1 ng/mL) remained a substantial stand-alone indicator of pCR or MRD (odds ratio: 10.712, 95% CI: 2.725-42.105, p &lt; 0.001). Furthermore, supplemental analyses revealed that the ADT plus apalutamide cohort exhibited an augmented serum response rate, which, in turn, reduced the post-intervention pre-RP PSA content. Based on our genetic profiling of the neoadjuvant apalutamide cohort demonstrated high-frequency deleterious changes in the AR axis (30.3%), followed by TP53 mutations (15.15%). Patients with defective AR axis experienced a remarkably shorter median BCR duration relative to patients with other or no genetic alterations (52.5 days vs. 286 and 336 days, respectively, p &lt; 0.0001). Furthermore, using multivariate analysis, we demonstrated that achieving pCR or MRD (hazard ratio [HR]: 0.170, 95% CI: 0.061-0.477, p &lt; 0.001) and presence of defective AR signaling (HR: 11.193, 95% CI: 3.499-35.806, p &lt; 0.001) were strong stand-alone indicators of BCR.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;Herein, we demonstrated the superior performance of ADT plus apalutamide in achieving pCR or MRD and in extending BCR duration among HRPC patients. Post-intervention pre-RP PSA content as well as genetic shifts, especially in the AR axis, are critical indicators of patient pathological and clinical outcomes. These findings","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"198-206"},"PeriodicalIF":2.6,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142570203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Personalized Medicine: Leave no Patient Behind; Report From the 2024 Coffey-Holden Prostate Cancer Academy Meeting. 个性化医疗:科菲-霍尔登前列腺癌学院 2024 年会议报告:不让一个患者掉队。
IF 2.6 3区 医学
Prostate Pub Date : 2025-02-01 Epub Date: 2024-11-27 DOI: 10.1002/pros.24826
Andrea K Miyahira, Marina Sharifi, Lisa N Chesner, Asmaa El-Kenawi, Roni Haas, Laura A Sena, Alok K Tewari, Kenneth J Pienta, Howard R Soule
{"title":"Personalized Medicine: Leave no Patient Behind; Report From the 2024 Coffey-Holden Prostate Cancer Academy Meeting.","authors":"Andrea K Miyahira, Marina Sharifi, Lisa N Chesner, Asmaa El-Kenawi, Roni Haas, Laura A Sena, Alok K Tewari, Kenneth J Pienta, Howard R Soule","doi":"10.1002/pros.24826","DOIUrl":"10.1002/pros.24826","url":null,"abstract":"<p><strong>Introduction: </strong>The 11th Annual 2024 Coffey - Holden Prostate Cancer Academy (CHPCA) Meeting, was themed \"Personalized Medicine: Leave No Patient Behind,\" and was held from June 20 to 23, 2024 at the University of California, Los Angeles, Luskin Conference Center, in Los Angeles, CA.</p><p><strong>Methods: </strong>The CHPCA Meeting is an academy-styled annual conference organized by the Prostate Cancer Foundation, to focus discussion on the most critical emerging research that have the greatest potential to advance knowledge of prostate cancer biology and treatment. The 2024 CHPCA Meeting was attended by 75 academic investigators and included 37 talks across 8 sessions.</p><p><strong>Results: </strong>The meeting sessions focused on: novel human, mouse and systems biology research models, novel immunotherapies for prostate cancer, efforts to overcome treatment resistance, the role of metabolism and diet in prostate cancer biology and as a therapeutic target, mechanisms that drive differentiation into neuroendocrine cancer subtypes, the evolving prostate cancer epigenome in disease progression and treatment resistance, and machine learning and advanced computational approaches for precision oncology.</p><p><strong>Discussion: </strong>This article summarizes the presentations and discussions from the 2024 CHPCA Meeting. We hope that sharing this knowledge will inspire and accelerate research into new discoveries and solutions for prostate cancer.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"211-226"},"PeriodicalIF":2.6,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142741337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信